SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : TITAN PHARMACEUTICAL (TTP) -- Ignore unavailable to you. Want to Upgrade?

To: NeuroInvestment who wrote (281)6/16/2004 12:02:08 AM
From: biofreak  Respond to of 362
 
Where do you get your info neuro?Today in the slides available at Shr web site ,they say they are keeping Spheramine.



To: NeuroInvestment who wrote (281)6/16/2004 12:06:40 AM
From: biofreak  Read Replies (1) | Respond to of 362
 
"Schering will shift its research and development resources from non-core fields into core portfolio areas to fully exploit their potential. Therefore, all research and development activities in the area of Cardiovascular and Central Nervous System diseases (with the exception of Multiple Sclerosis and Spheramine in Parkinson's disease) will be terminated."


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News